Annotation of rs2071559
Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele G.
Age-related macular degeneration. No significant differences in best-corrected visual acuity (BCVA) changes or central subfield macular thickness (CSMT) changes were seen between baseline and 3 or 6 months of treatment between any of the genotypes.
From Publication
Gene
Variant
Phenotype Category
Association Significance
PharmGKB ID
Score More info on scoring
Evidence for Clinical Annotations
This annotation has been used as evidence for the following clinical annotations.
Study Parameters
1.
Study type
Study size
Association p-value
Biogeographical group More info on groups
Population description
Age Group: 60 years or older. p-value refers to change in CSMT between baseline and 3 months of treatment.
2.
Study type
Study size
Association p-value
Biogeographical group More info on groups
Population description
Age Group: 60 years or older. p-value refers to change in BCVA between baseline and 3 months of treatment.
3.
Study type
Study size
Association p-value
Biogeographical group More info on groups
Population description
Age Group: 60 years or older. p-value refers to change in BCVA between baseline and 6 months of treatment.
4.
Study type
Study size
Association p-value
Biogeographical group More info on groups
Population description
Age Group: 60 years or older. p-value refers to change in CSMT between baseline and 6 months of treatment.
Note: Alleles in PharmGKB are mapped to the positive chromosomal strand. Therefore, variants in genes on the "minus" strand (eg. VKORC1) are complemented in PharmGKB annotations.